Mutator bacteria as a risk factor in treatment of infectious diseases
about
Dynamics of success and failure in phage and antibiotic therapy in experimental infectionsEvolution of mutation rates in bacteriaAntibiotic treatment enhances the genome-wide mutation rate of target cellsDeciphering Evolutionary Mechanisms Between Mutualistic and Pathogenic SymbiosesRecombination between ccrC genes in a type V (5C2&5) staphylococcal cassette chromosome mec (SCCmec) of Staphylococcus aureus ST398 leads to conversion from methicillin resistance to methicillin susceptibility in vivo.Hypermutable and fluoroquinolone-resistant clinical isolates of Staphylococcus aureus.Wider access to genotypic space facilitates loss of cooperation in a bacterial mutator.Noise-driven heterogeneity in the rate of genetic-variant generation as a basis for evolvability.Experimental adaptation of Salmonella typhimurium to miceDrug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rateMutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.Diversify or die: generation of diversity in response to stress.Lytic phages obscure the cost of antibiotic resistance in Escherichia coli.Optimizing drug exposure to minimize selection of antibiotic resistance.A non-canonical mismatch repair pathway in prokaryotesHypermutation and stress adaptation in bacteria.Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.The balance between mutators and nonmutators in asexual populations.Weak mutators can drive the evolution of fluoroquinolone resistance in Escherichia coli.Lack of association between hypermutation and antibiotic resistance development in Pseudomonas aeruginosa isolates from intensive care unit patientsFosfomycin and rifampin disk diffusion tests for detection of Escherichia coli mutator strains.The bacterial insertion sequence element IS256 occurs preferentially in nosocomial Staphylococcus epidermidis isolates: association with biofilm formation and resistance to aminoglycosides.Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion.Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.Resistance to antimicrobial peptides and stress response in Mycoplasma pulmonis.Intermediate mutation frequencies favor evolution of multidrug resistance in Escherichia coli.Evolution of Mutation Rates in Rapidly Adapting Asexual Populations.Induction and inhibition of ciprofloxacin resistance-conferring mutations in hypermutator bacteria.Antibiotic resistance and hypermutability of Escherichia coli O157 from feedlot cattle treated with growth-promoting agents.High relatedness selects against hypermutability in bacterial metapopulations.Resolving the evolutionary paradox of genetic instability: a cost-benefit analysis of DNA repair in changing environments.
P2860
Q24803578-D2345616-7E7E-4DE5-BDC3-244AF95B761DQ28238561-32414DB3-4320-46ED-911F-79CED6E0DEF2Q28386555-8610D4F8-D91E-4172-9684-1E7194CBF658Q33490644-C3CB8F2E-12AA-4A1A-83D6-7F05B59669D8Q33613780-38DC8DC2-618B-48DC-9C4F-DE758C7BF741Q33770211-17A2EB3B-6A3D-4176-AB64-873CE04BD262Q33833686-C57E2194-C035-4574-985A-E5D46164198FQ33895328-C0749F4B-4111-474B-BBD0-6FDD03F2CC16Q34569582-65A8FE01-D21F-495B-9DE3-4F0524DE4BA5Q34975227-8FBDEDC7-9862-4B6F-8D86-1E20620D0127Q36048167-47AD714A-CEC0-4176-BA37-2B6FEE67DBECQ36178618-B86E7D38-9A5C-4C00-B080-939190492D64Q36756563-ADA537A1-4DDB-4769-AF3F-4D330C653DC5Q36903693-6D1B1566-17C6-489D-A475-956FEFBD2491Q37622415-75D601CE-BECD-4972-AABA-949F116CCC38Q37922538-ED0FD66B-CBEA-4318-A27E-AA4005B2E059Q37957839-31E30236-1AA8-4C0B-9866-DA90B569B77EQ38517985-67C36FBB-A774-4A04-A2A4-B17EBB07840BQ38665569-A7537785-3A63-4804-A68E-2C63552F6508Q39955018-38CA5DA7-0CC7-4776-9FA7-2318E204CB1FQ39990097-EDFAAD32-D859-4002-A46E-A483C3E5243CQ40469782-C57E5EF3-72F3-406D-986D-F195A46C3E8AQ40968218-8BDDB400-9F93-4B20-A52F-396D88DCC16EQ41991607-0F030669-20D2-4AF2-A09E-BAA8433320F6Q42112602-AB107B59-5DF8-47AA-9BAF-43D48D0C06E1Q42705384-BF39AFA9-BC82-4F69-8BEF-2839D71C4B14Q42741265-A4A5841A-945F-488A-A789-62B525902FE0Q43181792-DC58BA39-3F85-4BCB-BF45-A448619CDEEBQ46813853-3BBB44FC-228D-4A16-8AD9-7FCACA47539FQ51711564-4C5D9597-07A3-444E-9556-768BBE5BB65CQ52000126-DEB4D2BA-49A2-4E58-8223-EFED71CBA3FD
P2860
Mutator bacteria as a risk factor in treatment of infectious diseases
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Mutator bacteria as a risk factor in treatment of infectious diseases
@ast
Mutator bacteria as a risk factor in treatment of infectious diseases
@en
Mutator bacteria as a risk factor in treatment of infectious diseases
@nl
type
label
Mutator bacteria as a risk factor in treatment of infectious diseases
@ast
Mutator bacteria as a risk factor in treatment of infectious diseases
@en
Mutator bacteria as a risk factor in treatment of infectious diseases
@nl
prefLabel
Mutator bacteria as a risk factor in treatment of infectious diseases
@ast
Mutator bacteria as a risk factor in treatment of infectious diseases
@en
Mutator bacteria as a risk factor in treatment of infectious diseases
@nl
P2860
P50
P1476
Mutator bacteria as a risk factor in treatment of infectious diseases
@en
P2093
Ivan Matic
Michel Fons
P2860
P304
P356
10.1128/AAC.46.3.863-865.2002
P407
P577
2002-03-01T00:00:00Z